A Pharmacogenomics Study of TAS-102
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/100784
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: investigational material(s)
Generic name etc : TAS-102
INN of investigational material :
Therapeutic category code : 422 Antimetabolic agents
Dosage and Administration for Investigational material : 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
control material(s)
Generic name etc : Placebo
INN of investigational material :
Therapeutic category code : --- Other
Dosage and Administration for Investigational material : Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Primary outcome(s): Correlation between the relative factor and disease control rate, overall survival, or progression-free survival
RECIST (ver.1.1)
Study Design: Multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study
创建时间：
2012-08-15
